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Abstract
Oligomeric amyloid-β (Aβ) interferes with long term potentiation (LTP) and cognitive processes,
suggesting that Aβ peptides may play a role in the neuronal dysfunction which characterizes the
early stages of Alzheimer’s disease (AD). Multiple lines of evidence have highlighted RAGE
(receptor for advanced glycation end-products) as a receptor involved in Aβ-induced neuronal and
synaptic dysfunction. In the present study, we investigated the effect of oligomeric soluble Aβ1–42
on LTP elicited by the stimulation of different intracortical pathways in the mouse visual cortex. A
variety of nanomolar concentrations (20– 200 nM) of Aβ1–42 were able to inhibit LTP in cortical
layer II-III induced by either white matter (WM-Layer II/III) or the layer II/III (horizontal
pathway) stimulation, whereas the inhibition of LTP was more susceptible to Aβ1–42, which
occurred at 20 nM of Aβ, when stimulating layer II-III horizontal pathway. Remarkably, cortical
slices were resistant to nanomolar Aβ1–42 in the absence of RAGE (genetic deletion of RAGE) or
blocking RAGE by RAGE antibody. These results indicate that nanomolar Aβ inhibits LTP
expression in different neocortical circuits. Crucially, it is demonstrated that Aβ-induced reduction
of LTP in different cortical pathways is mediated by RAGE.
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INTRODUCTION
Extensive deposition of amyloid-β (Aβ) leading to the formation of plaques is considered
one of the key pathological features of Alzheimer’s disease (AD) [1]. Aβ derives from the
cleavage of amyloid-β protein precursor and exists in a variety of forms including
monomers, oligomers, protofibrils, and fibrils [2].
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Previous studies have shown that soluble oligomeric Aβ1–42, including the human naturally
secreted peptide, acutely inhibits long-term potentiation (LTP) in the hippocampus [3–
5],one of the main forms of synaptic plasticity that is thought to underlie learning and
memory [6]. These results are in agreement with recent observations in both AD patients
and AD-type mouse models showing that impairment of memory and synaptic deficit occur
prior to extensive extracellular deposition of Aβ in the brain [7–12]. Oligomeric Aβ plays a
key pathogenic role in neuronal and synaptic dysfunction, which is associated with the early
phase of AD progression [13]. Our recent study [14] further supports the concept that
oligomeric Aβ is able to disrupt LTP induction in the entorhinal cortex,an area intimately
connected to the hippocampus which is involved in learning and memory. Furthermore,
histopathological studies have demonstrated that the hippocampus and the parahippocampal
formation are the earliest affected regions during AD, suggesting a precise chronological
(and hierarchical) order of involvement: from limbic to associative and from associative to
primary cortical areas including the visual cortical areas [15,16]. However, recent studies
have highlighted an apparent dichotomy between the progress of histopathological findings
in different brain areas and the occurrence of visual dysfunctions in AD patients. In
particular, clinical studies support a link between cognitive performance and visual
dysfunction even at an early stage of AD. Impairment of higher order visual processing,
such as the loss of color discrimination, stereoacuity, contrast sensitivity, and backward
masking, have been frequently described in AD patients [17–19]. The gradual loss of
memory and attention are also frequently accompanied by alteration of visuospatial function
in animal models and AD patients [20,21]. Finally, the cholinergic deficit associated with
cognitive impairment represents an early event in the visual cortex of AD patients [22].
These observations imply an impact of visual synaptic dysfunction on the pathogenesis of
AD but the mechanism by which visual synaptic function is linked to Aβ remains unclear.
RAGE (receptor for advanced glycation end-products) is a multiligand receptor of the
immunoglobulin superfamily that functions as a cell surface binding site for Aβ [23].
Importantly, RAGE possesses high affinity binding to oligomeric Aβ [24]. Growing
evidence highlights RAGE as a factor that mediates and amplifies the effects of Aβ on
neuronal target cells, some of which are reported in detail: i) enhanced expression of RAGE
in Aβ enriched environments [25–27]; ii) expression of RAGE on cells critical for
neurodegenerative pathology (neurons, glia, endothelial cells, pericytes of the blood brain
barrier cells,microglia) [28,29]; and iii) RAGE binds cytokine-like mediators exerting
proinflammatory activity [30]. Our recent studies provide substantial evidence that Aβ-
induced suppression of LTP in hippocampus [7] and entorhinal cortex [14] is mediated by
RAGE.
In the present study, we extended our previous findings on the entorhinal cortex by
investigating whether: i) oligomeric Aβ1–42 inhibits LTP in occipital visual cortex; ii) LTP
elicited by stimulation of different intracortical connections is sensitive to different
concentrations of Aβ1–42; and iii) there is a role for RAGE in Aβ-mediated synaptic
function in occipital visual cortex. We examined the effects of oligomeric Aβ1–42 at a
variety of nanomolar concentrations (2–200 nM) on basic synaptic transmission and
expression of LTP and determined the effects of RAGE abrogation on Aβ-induced synaptic
function in occipital visual cortex lacking RAGE or in which endogenous RAGE was
blocked by a specific RAGE antibody.
MATERIALS AND METHODS
Procedures followed in experimental animal subjects were done in accordance with the
guidelines approved by European Community Council Directive and Italian Ministry of
Health (129/2000-A, December 13, 2000).
Origlia et al. Page 2
J Alzheimers Dis. Author manuscript; available in PMC 2013 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Homozygous RAGE null mice
Homozygous RAGE-null mice were generated and characterized as described previously
[31,32]. Homozygous RAGE null mice were backcrossed for more than 10 generations into
C57BL/6 mice before study. Male RAGE null and littermate control mice were used.
Pharmacological agents and MALDI-MS analysis
Solutions containing synthetic Aβ1–42 or the reverse peptide (42–1) (Biosource, Ca, USA)
were prepared following methods previously described [14,33, 34]. Briefly, the lyophilized
peptide was suspended in 100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; Sigma-Aldrich),
and HFIP was allowed to evaporate. The resulting peptide films were stored at −20°C.
Twenty-four hours prior to use, the aliquots were added to DMSO (Sigma-Aldrich, MO,
USA) and sonicated for 10 minutes. Oligomeric Aβ1–42 was obtained by diluting an aliquot
of Aβ1–42/DMSO solution with a small volume of normal recording bath solution (ACSF
solution, see slice preparation), vortexing for 30 seconds, and then incubating at 4°C for 16
hours. Before using, oligomeric Aβ was added to ACSF to obtain final concentrations in the
nanomolar range. This synthetic Aβ has been characterized both biochemically and
electrophysiologically, showing similar biological effects at low nanomolar concentrations
as naturally secreted oligomers of Aβ [35]. Oligomeric composition of Aβ1–42 solutions was
characterized by using mass spectrometry. Briefly, protein samples were analyzed using the
modified thin-layer method of Cadene and Chait [36]. The matrix used was a saturated
solution of α-cyano-4-hydroxycinnamic acid in 3:1:2 (v/v/v/) formic acid/ water/
isopropanol. The protein solution was mixed 1:5 with matrix solution and spotted on the
sample plate prepared with a thin layer of α-cyano-4-hydroxycinnamic acid and allowed to
dry. Standard solutions of 6 mM apomyoglobin and 15 mM bovine serum albumin were
mixed with matrix and spotted in the same way for use as calibrants. Spectra were acquired
on a Voyager-DE Pro (Applied Biosystems, Foster City, CA) operating in linear mode.
Instrument settings were as follows: accelerating voltage, 25000V; grid voltage, 93%;
extraction delay time, 1050 ns; laser intensity 2200–2700.
Specific antibodies to RAGE were described in previous studies [23] and purified rabbit
non-immune IgG were used as control (Bethyl, TX, USA).
Slice preparation
Animals were deeply anesthetized by urethane (20% solution, 0.1 ml/100g b.w.) via
intraperitoneal injection and then decapitated after tail pinch reflex disappearance. The brain
was rapidly removed and 400 µm thick coronal sections of the occipital pole were sliced by
a vibratome. All steps were performed in ice cold ACSF solution (in mM: NaCl, 119; KCl,
2.5; CaCl2, 2; MgSO4, 1.2; NaH2PO4, 1; NaHCO3, 26.2; glucose, 11) bubbled with 95%
O2/5% CO2. Prior to recording, slices were stored for at least 1 hour in a recovery chamber
containing oxygenated ACSF solution at room temperature. During electrophysiological
recordings, the slices were perfused at 2.5–3 ml/min with oxygenated ACSF, at 33 ± 1°C.
Electrophysiological recordings
Extracellular field potentials (FPs) were evoked in visual cortex slices via a tungsten
concentric bipolar stimulating electrode placed at the white matter (WM)/ layer VI border to
stimulate vertical intracortical pathway (Fig. 1A) or in layer II/III to stimulate horizontal
intracortical pathway (Fig. 1B), while the recording electrode (pulled glass capillaries, OD.
1.0 mm-ID 0.78 mm) was placed in layer II/III (Fig. 1A, B). The amplitude of the FPs was
used as a measure of the evoked population excitatory current [37,38]. Baseline responses
were obtained with a stimulation intensity that yielded 50–60% of maximal amplitude. All
FPs had peak latency between 4.5 to 6 ms. FP amplitude was monitored every 20 seconds
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and averaged every three responses by an online data acquisition software [39]. After 15
minutes of stable baseline, recording high frequency stimulation (HFS, three trains of 100
pulses at 100 Hz, 10 second interval) was used to induce LTP. LTP magnitude was
measured as the average of FP amplitudes between the 40th and the 50th min after HFS.
Values were expressed as mean ± SEM percentage change relative to their mean baseline
amplitude.
Aβ peptides were applied through general perfusion for 10 minutes starting from 5 minutes
before HFS.
Statistical analysis
Statistical comparisons were performed by applying two-way ANOVA for repeated
measures followedby all pair-wise multiple comparison test. Differences were considered
significant when p < 0.05.
RESULTS
A brief application of oligomeric Aβ1–42 affects LTP in cortical layer II/III
We used synthetic Aβ1–42 at nanomolar concentration ranges, i.e., at concentrations lower
than those used for neurotoxicity and cell death [14]. Before application, we characterized
the oligomeric composition of synthetic Aβ1–42 by mass spectrometry analysis. There were
monomers, dimers, and trimers in the Aβ preparation (Fig. 2).
LTP was reliably elicited by high frequency stimulation (HFS) of the white matter in mouse
slices containing visual cortical areas (Fig. 3A) in agreement with the previous reports
[37,38,40]. The amount of LTP 50 minutes after HFS was 139 ± 2% of baseline (n =18
slices, 8 mice; Fig. 3A). Bath application for 10 minutes of 200 nM Aβ1–42 or the reverse
control peptide (42–1, 200 nM) did not result in a significant change of FP amplitudes during
baseline recording (Fig. 3C), or modification of input/output curves (data not shown),
similarly to those reported in entorhinal cortex slices [14]. These results suggest that Aβ1–42
in the nanomolar range does not affect basal synaptic transmission. When 200 nM Aβ1–42
was bath-applied for 10 minutes starting 5 minutes before HFS delivery in interleaved
experiments, it was able to completely inhibit LTP expression (94 ± 9%, n = 9, 6 mice; p <
0.05 vs. vehicle treated slices; Fig. 3B). A lower concentration of Aβ (20 nM), did not affect
LTP in layer II/III for the stimulation of WM (132 ± 9%, n = 6, 3 mice; Fig. 2B). LTP
amplitude was unaffected in slices treated with the reverse peptide Aβ42–1 (200 nM) (132 ±
10%, n = 6, 3 mice; Fig. 3D).
To investigate whether the vulnerability of LTP to Aβ1–42 is input specific, we applied
Aβ1–42 while LTP was induced by the stimulation of a different synaptic pathway in the
occipital cortex. The recording electrode was placed in layer II/III as usual, while the
stimulating electrode was placed in the same layer II//III, laterally to the recording electrode,
to stimulate horizontal intracortical connections [37]. In control vehicle treated slices (n = 8,
4 mice), the mean LTP elicited by HFS of the horizontal layer II/III pathway was 145 ± 7%,
(Fig. 4A). LTP was completely inhibited by bath perfusion of 200 nM Aβ1–42 (105 ± 4%, n
= 7, 4 mice, Fig. 4B). In contrast to the observation for the stimulation of the WM layer II/
III vertical pathway, 20nM Aβ1–42 was sufficient to block LTP elicited by the stimulation of
the horizontal layer II/III pathway (108 ± 1%, n = 6, 3 mice vs. 145 ± 7%, n = 8 in vehicle
treated slices, p < 0.05; Fig. 4B). Slices treated with 2 nM Aβ1–42 had a normal LTP (138 ±
5%, n =9, 4 mice; Fig. 4B). Thus, LTP sensitivity to Aβ1–42 concentrations shifts towards
lower values when stimulating the horizontal connections in layer II/III in comparison with
the stimulation of the vertical connections from WM to layer II/III. These results indicate
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that the horizontal connection in layer II/III of neocortex is highly susceptible to Aβ-induced
synaptic insults.
RAGE deficiency rescues Aβ1–42-induced inhibition of LTP in cortical layer II/III
Previous studies showed that RAGE mediates Aβ induced synaptic plasticity impairment in
the hippocampus [7] and entorhinal cortex [14]. To test whether RAGE was involved in
Aβ1–42 -dependent impairment of LTP in neocortical areas, we examined the effect of a
brief application of Aβ1–42 on LTP expressed in occipital slices from RAGE null mice or
slices pretreated with anti-RAGE IgG The basic FP features (amplitude, latency, wave-
shape, input/output curves) did not differ between RAGE null and age-matched WT mice
(data not shown), in agreement with the findings reported in entorhinal cortex slices [14].
Moreover, a deficiency of RAGE (RAGE null mice) and a blockade of RAGE by specific
antibodies to RAGE (slices incubated with anti-RAGE IgG, 2.5 µg/ml for at least 2 hours
prior to recordings) did not affect LTP expression (Fig. 5A). LTP elicited by the stimulation
of WM-layer II–III vertical pathway was 148 ± 5% (n = 8, 4 mice, p > 0.05 vs. control
vehicle slices) in RAGE null mice and 145 ± 6% in slices pre-treated with anti-RAGE IgG
(n = 6, 3 mice; p > 0.05 vs. control vehicle slices). Similarly, the absence of RAGE did not
affect the magnitude of LTP elicited by the stimulation of the horizontal pathway in layer II-
III (138 ± 4% in RAGE null slices n = 9, 4 mice; p > 0.05 vs. control slices, Fig. 5C). These
results indicate that RAGE deficiency or blockade of RAGE by specific antibody to RAGE
does not interfere with normal synaptic function. However, abrogation of RAGE rescued the
reduction of LTP induced by Aβ. When Aβ1–42 (200 nM) was bath-applied in slices from
RAGE null mice or slices pre-treated with anti-RAGE IgG, the LTP elicited by stimulation
of WM-layer II-III pathway was normal (Fig. 5B). The LTP amplitude in RAGE null (145 ±
11%, n = 8, 4 mice) and anti-RAGE IgG-incubated (142 ± 12 %, n=6, 3 mice) slices treated
with Aβ was significantly increased (p < 0.05) with respect to LTP in slices treated with Aβ
alone while the values were similar when compared with those obtained in RAGE null or
anti-RAGE IgG slices without Aβ. Similarly, the absence or blockade of RAGE was able to
re-establish a normal LTP elicited by stimulation of layer II-III horizontal pathway in Aβ
treated slices (RAGE null plus Aβ = 144 ± 14, n = 9, 5 mice; Fig. 5D; p < 0.05 vs. vehicle
plus Aβ). Thus, the absence of RAGE or its functional blockade makes cortical LTP
resistant to nanomolar concentrations of Aβ1–42.
DISCUSSION
Our results confirm and extend previous observations in the parahippocampal area, the
entorhinal cortex, indicating that non-toxic oligomeric Aβ1–42 affects LTP through RAGE
activation. In particular, we report here that: i) Aβ-RAGE signaling is involved in LTP
alteration in a neocortical area, the visual cortex; and ii) Aβ1–42 at concentrations of 20 and
200 nM differently affects the LTP elicited by stimulation of two different intracortical
pathways in the visual cortex.
Oligomeric forms of Aβ play a critical role in the pathogenesis of AD. Aβ contributes to the
early impairment of cognitive functions such as learning and memory [41,42]. The early
signs of functional impairment precede the extensive neurodegeneration with a significant
accumulation of Aβ in brain during a middle/late phase of AD. The basic mechanism of this
functional impairment is thought to involve perturbation of synaptic efficiency in different
brain areas, and to be strictly associated with an increased extracellular level of Aβ. In
agreement with this hypothesis, oligomeric Aβ affects LTP in the hippocampus [5,33,43]
and entorhinal cortex [14], two brain areas which play a fundamental role in the learning and
memory process, and which are affected in AD [15].
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Histopathological analysis of postmortem tissue has revealed that certain limbic regions, in
particular hippocampus and the parahippocampal formation, are among the first affected
during AD progression [15]. The visual cortex is usually considered to be relatively spared
during AD even if all of the typical histopathological markers such as tangles, amyloid
plaques, and cholinergic deficits nevertheless have been reported in this area [22,44,45].
Furthermore, deficits in higher order visual processing in AD patients have been described,
including losses in color discrimination, stereoacuity, contrast sensitivity, and backward
masking [17–19], suggesting a link between visual dysfunction and cognitive performance
even at the early stages of AD [20–22]. These observations highlight a discrepancy between
the chronological order of involvement of different brain areas and the appearance of visual
dysfunction. In the present study, we hypothesized that oligomeric Aβ plays an important
role in the neuronal dysfunction in different brain areas, including the visual cortex. In
particular, we hypothesized that at an early stage in the disease process, when levels of
deposited Aβ are low, cortical visual function might be impaired by Aβ peptides. Indeed, the
long term synaptic plasticity associated with LTP is altered by oligomeric Aβ1–42 in the
nanomolar range of concentrations (20– 200 nM). These concentrations of Aβ were not
sufficient to induce cell death in primary cultures of cortical neurons [14]. Thus, oligomeric
Aβ1–42 disrupts the synaptic function prior to neuronal death, as shown by a reduction of
LTP in the visual cortex as well as hippocampus [7] and entorhinal cortex [14].
The advantage of studying the visual cortex is that both basal synaptic transmission and
long-term synaptic plasticity are well characterized in slices containing this area [40,46,47],
both at the level of its cortical layers and intra-cortical connections. It is intriguing that, as
we have demonstrated, the LTP elicited through stimulation of horizontal layer II/III
pathway is altered by a lower concentration of Aβ1–42 (20 nM) as compared with the LTP
elicited through stimulation of the WM-layer II/III vertical pathway, which is affected only
by a higher concentration of Aβ (200 nM). Thus synaptic disruption induced by oligomeric
Aβ differs within intra-cortical pathways in the occipital cortex. The present study, together
with previous reports [48, 49] showing the presence of laminar differences within single
brain areas in AD progress, raises the important question of whether the pattern of AD
reflects the sensitivity of different neurons and/or synaptic connections to pathogens
including Aβ1–42. Indeed, our results indicate that the synaptic connections in the visual
cortex are more vulnerable to Aβ1–42 (20 nM)-induced reduction of LTP compared to other
brain areas, such as the hippocampus [5] and entorhinal cortex [14], in which suppression of
LTP occurs at 200 nM of Aβ1–42. What is the functional implication of these results? It is
well known that different intra-cortical connections convey specific and distinct aspects of
sensory related information necessary for cognitive functions. For instance, the WM matter
layer II/III vertical pathway is related to codification of sensory stimuli, while the horizontal
pathway in layer II/III is more closely to elaboration and retrieval of previously stored
sensory input [50]. Thus, our results suggest that during the early phase of AD characterized
by low level Aβ, the visual function related to elaboration and retrieval of previously stored
visual input is more sensitive to Aβ-dependent synaptic disruption. This may also help
explain the early visual dysfunction observed in AD patient [17– 22]. Aβ has previously
been linked to LTP through its effect on glutamate receptor subtypes [5,51–54]. A number
of recent studies have identified RAGE as a receptor capable of binding Aβ at the cell
surface [23, 26], in both monomeric and oligomeric form [24,55]. RAGE immunoreactivity
is present at the sites of Aβ deposition increasing Aβ aggregation at the cell membrane [23].
All together, these studies identify Aβ signaling through RAGE as a key event for processes
involved in oxidative stress, inflammation, and neurotoxicity. Furthermore, RAGE has been
implicated as an important receptor mediating Aβ induced neuronal and synaptic
dysfunction both in hippocampus [7] and entorhinal cortex [14]. The present results are thus
extended to the neocortexand show that RAGE deficiency or functional blockade of RAGE
by specific antibodies counteracts the LTP dysfunction induced by oligomeric Aβ1–42.
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These studies significantly increase the body of evidence that activation of RAGE by Aβ
represents a key and an early step leading to neuronal dysfunction before amyloid plaque
deposition in the visual cortex.
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Fig. 1.
Schematic drawing of cortical slices and position of electrodes. (A) Representation of
vertical WM-layer II/III pathway; the stimulating electrode(s) is placed at WM/layer VI
boarder while the recording pipette (r) is positioned in layer II/III (corresponding to 300 µM
below pial surface). (B) For stimulation of intracortical horizontal pathway, recording- (r)
and stimulating- (s) electrodes were placed within the same layer (II/III).
Origlia et al. Page 11
J Alzheimers Dis. Author manuscript; available in PMC 2013 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Mass spectrometry analysis of Aβ1–42. Oligomeric composition of Aβ1–42 preparation was
characterized by using mass spectrometry. Spectra were acquired on a Voyager-DE Pro
(Applied Biosystems, Foster City, CA) as described in Materials and Methods. The main
signals corresponded to the molecular ions of Aβ monomers, dimers, and trimers.
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Fig. 3.
Inhibitory effect of Aβ1–42 on LTP elicited by the stimulation of vertical WM-Layer II/III
pathway in cortical slices. (A) Under control conditions, LTP expression is induced by HFS
of WM, applied after 15 minutes of baseline recording. (B) LTP is inhibited by Aβ1–42 200
nM (bath applied for 10 minutes starting from 5 minutes before HFS, dark bar; gray circles)
while no effect is observed for a lower concentration of Aβ (20 nM, filled squares).(C) No
effect on basal synaptic transmission was observed in the presence of Aβ1–42 (200 nM) or
the reverse control peptide Aβ42–1 (200 nM) (dark bar represents application time of Aβ
peptides). (D) No effect on LTP expression was observed in the presence of the control
reverse peptide Aβ42–1 (200 nM). The top inserts of panels A–B show representative field
potentials recorded before and 50 minutes after HFS (vertical scale bar = 0.5 mV; horizontal
scale bar = 5 ms).
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Fig. 4.
Aβ1–42 inhibits LTP elicited by the stimulation of the horizontal layer II/III ortical pathway.
(A) LTP expression invehicle treated slices after HFS of layer II/III (horizontal pathway).
(B) Effect of 10 minute bath application (horizontal dark bar) of different Aβ1–42
concentrations (2, 20 and 200 nM) on horizontal pathway LTP expression.
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Fig. 5.
Blockade of RAGE protects against Aβ1–42 (200 nM)-induced impairment of cortical LTP.
(A) LTP elicited by HFS of WM-Layer II/III pathway is unaffected in slices from RAGE
null mice (open circles) or in slices pre-incubated with anti-RAGE IgG (2.5 µg/ml for 2
hours, filled triangles). (B) Bath application (dark bar) of Aβ42–1 (200 nM) is unable to
inhibit LTP elicited by HFS of WM-Layer II/III pathway in slices from RAGE null mice
(open circles) or in slices pre-incubated with anti RAGE IgG (2.5 µg/ml for 2 hours, filled
triangles). In (A) and (B) top inserts show representative field potentials recorded before and
50 minutes after HFS (vertical scale bar = 0.5 mV; horiz. scale bar = 5 ms). (C) LTP elicited
by HFS of horizontal layer II/III pathway is not altered in cortical slices from RAGE null
mice. (D) RAGE deficiency (RAGE null slices) rescues normal LTP elicited by HFS of
horizontal layer II/III pathway in Aβ-treated cortical slices (dark bar).
Origlia et al. Page 15
J Alzheimers Dis. Author manuscript; available in PMC 2013 July 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
